In the article on targeting LPAAT-β in gynecologic cancer in the October 15, 2005 issue of Cancer Research (1), it should be noted that Dr. Gregory M. Springett's research was performed at the Memorial Sloan-Kettering Cancer Center, Developmental Chemotherapy Laboratory, Department of Medicine; he is currently at the H. Lee Moffitt Cancer Center, Drug Discovery Program and Department of Interdisciplinary Oncology. Also, the following should have appeared in the Acknowledgment: We thank the Memorial Sloan-Kettering Cancer Center Molecular Cytology Core for assistance with the confocal microscopy studies, Cyrus Hedvat for constructing the tissue microarrays, Mario Leitao for assistance in obtaining clinical follow-up information, and Jeni Moses for assistance in compound screening.

Springett GM, Bonham L, Hummer A, Linkov I, Misra D, Ma C, Pezzoni G, Di Giovine S, Singer J, Kawasaki H, Spriggs D, Soslow R, Dupont J. Lysophosphatidic acid acyltransferase-β is a prognostic marker and therapeutic target in gynecologic malignancies.
Cancer Res